Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Mar 7, 2017
Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Mar 1, 2017
Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017
Mar 8, 2017 at 8:40 AM ET
Mar 7, 2017 at 1:30 PM PT